Search Results - "Richert, John R."

Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis by Fischer, Jill S., Priore, Roger L., Jacobs, Lawrence D., Cookfair, Diane L., Rudick, Richard A., Herndon, Robert M., Richert, John R., Salazar, Andres M., Goodkin, Donald E., Granger, Carl V., Simon, Jack H., Grafman, Jordan H., Lezak, Muriel D., O'Reilly Hovey, Kathleen M., Kawczak Perkins, Katherine, Barilla-Clark, Danielle, Schacter, Mark, Shucard, David W., Davidson, Anna L., Wende, Karl E., Bourdette, Dennis N., Kooijmans-Coutinho, Mariska F.

“…Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis by Castro, Henry J, Mendez-Lnocencio, Julia I, Omidvar, Berna, Omidvar, Jemal, Santilli, John, Nielsen, Jr, H S, Pavot, Alfred P, Richert, John R, Bellanti, Joseph A

“…Although several reports suggest that bee venom may be an effective treatment for patients with multiple sclerosis (MS), patients may be subjected to real…”
Get more information

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis by Stuart, William H, Cohan, Stanley, Richert, John R, Achiron, Anat

“…Multiple sclerosis (MS) is a complex, incurable disease. Treatment consists of lifelong disease and symptom management. FDA-approved therapies for relapsing MS…”
Get full text

Structure-Based Discovery of Nonpeptidic Small Organic Compounds To Block the T Cell Response to Myelin Basic Protein by Koehler, Niklas K. U, Yang, Chao-Yie, Varady, Judith, Lu, Yipin, Wu, Liu, Ming, Yin, Daxu, Bartels, Margreet, Xu, Bi-ying, Roller, Peter P, Long, Ya-qiu, Li, Peng, Kattah, Michael, Cohn, Marjorie L, Moran, Kelly, Tilley, Eurona, Richert, John R, Wang, Shaomeng

“…We have utilized a computational structure-based approach to identify nonpeptidic small organic compounds that bind to a human leukocyte antigen (HLA) DR1301…”
Get full text

Sp3 Expression in Immune Cells: A Quantitative Study by Grekova, Maria C, Salerno, Kilian, Mikkilineni, Radha, Richert, John R

“…We previously reported the lack of expression of the bifunctional transcription factor Sp3 in peripheral blood mononuclear cells from most patients with…”
Get full text

Human transcription factor Sp3: genomic structure, identification of a processed pseudogene, and transcript analysis by Moran, Kelly M., Crusio, Robbert H.J., Chan, Connie H., Grekova, Maria C., Richert, John R.

“…The human transcription factor Sp3 has been widely studied at the translational level and has been described as a regulatory factor for a number of genes. Sp3…”
Get full text

Role of an internal ribosome entry site in the translational control of the human transcription factor Sp3 by Hernandez, Eric Moore, Chan, Connie H, Xu, Biying, Notario, Vicente, Richert, John R

“…Sp1 and Sp3 are transcription factors involved in the regulation of numerous genes involved in oncogenesis. Sp3 is a bi-functional transcription factor with…”
Get more information

AUA as a translation initiation site in vitro for the human transcription factor Sp3 by Hernandez, Eric Moore, Johnson, Anna, Notario, Vicente, Chen, Andrew, Richert, John R

“…Sp3 is a bifunctional transcription factor that has been reported to stimulate or repress the transcription of numerous genes. Although the size of Sp3 mRNA is…”
Get more information

Localization of the human SP3 gene to chromosome 7p14–p15.2. The lack of expression in multiple sclerosis does not reflect abnormal gene organization by Grekova, Maria C, Scherer, Stephen W, Trabb, Jeffrey, Richert, John R

“…Sp3 belongs to a large family of transcription factors that bind GC/T box elements. We have previously demonstrated the deficient expression of Sp3 in…”
Get full text

Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides by MOHAN, Niveditha, EDWARDS, Evelyne T, CUPPS, Thomas R, OLIVERIO, Patrick J, SANDBERG, Glenn, CRAYTON, Heidi, RICHERT, John R, SIEGEL, Jeffrey N

Get full text

Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults by Cohn, M L, Robinson, E D, Faerber, M, Thomas, D, Geyer, S, Peters, S, Martin, M, Martin, A, Sobel, D, Jones, R

“…The measles-specific antibody responses of seronegative adolescents and young adults were evaluated after revaccination. Of 1650 previously vaccinated healthy…”
Get more information

CSF antibodies for dynorphin bind synthetic Staphylococcus aureus replication protein B 275-290 by Roy, B F, Dauphin, M M, Warden, D L, Pierce, P F, Richert, J R

Get more information

Adoptive Transfer of Experimental Allergic Encephalomyelitis: Incubation of Rat Spleen Cells with Specific Antigen by Richert, John R, Driscoll, Bernard F, Kies, Marian W, Alvord, Ellsworth C., Jr

“…Spleen cells from myelin basic protein (BP)-sensitized donor rats appear to be incapable of adoptively transferring experimental allergic encephalomyelitis…”
Get full text

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis: Current clinical perspectives on the treatment of multiple sclerosis by STUART, William H, COHAN, Stanley, RICHERT, John R, ACHIRON, Anat

Get full text

Open label gabapentin treatment for pain in multiple sclerosis by Houtchens, M K, Richert, J R, Sami, A, Rose, J W

“…Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem. Conventional therapy is…”
Get more information

Multiple Sclerosis: Current Status of Research and Treatment by Richert, John R.

Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

Eight-year immunogenicity and safety of interferon beta-la-avonex® treatment in patients with multiple sclerosis by HERNDON, Robert M, RUDICK, Richard A, GOODKIN, Donald, TOAL, Martin, RIESTER, Katherine, MUNSCHAUER, Frederick E, MASS, Michele K, SALAZAR, Andres M, COATS, Michael E, LABUTTA, Robert, RICHERT, John R, COHAN, Stanley L, GENAIN, Claude

Get full text

Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106 by Martin, R, Utz, U, Coligan, JE, Richert, JR, Flerlage, M, Robinson, E, Stone, R, Biddison, WE, McFarlin, DE, McFarland, HF

“…Multiple sclerosis (MS), a human demyelinating disease, is thought to be caused by an autoimmunologic process, and myelin basic protein (MBP) is considered a…”
Get full text